Abstract:Background: CD47 is a receptor widely expressed in human tumors, including lymphoma, AML, and many solid tumors. It interacts with its ligand SIRPα on macrophages, also found on dendric cells, to evade macrophage phagocytosis. CD47 is an important innate and adaptive immune checkpoint and is considered one of the most promising immuno-oncology targets since PD-1/PDL-1. Anti-CD47 antibodies and SIRPα fusion proteins are currently being developed for the treatment of various cancers. It is believed that CD47 expression on the surface of cancer cells is critical to the success of these therapies and if true, CD47 could become a predictive biomarker for the treatment of cancer and/or be developed as a companion diagnostic (CDx). It is thus prudent to have a robust, practical, and relevant clinical testing assay that can measure CD47 expression in the clinic. In this study, a CD47 IHC assay that can potentially be developed as a clinical testing assay was explored using preclinical FFPE samples of patient-derived xenograft (PDX) tumor models. The models used represent diverse cancer types and heterogeneity, are consistent and renewable for assay standardization, and are characterized by both transcriptomics and pharmacological testing. Methods: Tissue microarray (TMA) or FFPE slides of both lymphoma (37 PDX models) and breast cancer (38 PDX models) were prepared following standard histology procedure. A standard IHC staining protocol was performed in BondRx Automated IHC/ISH Slide Staining System (Leica) using a commercial anti-CD47 antibody (Abcam, ab218810). This was followed by whole slide imaging using the NanoZoomer NDP2.0-HT Digital Slide System (Hamamatsu) and quantified using the HALO™ image analysis software (Indica Labs), with pathologists’ peer review. The CD47 IHC score was also compared to the RNA expression, determined by whole transcriptome sequencing. Results: Thousands of PDX models of diverse tumor types have been created and fully characterized, including with RNA-seq and pathology data, and are accessible via Crown Bioscience’s HuBase database. TMAs have also been prepared for selected disease sample panels. CD47 IHC staining of lymphoma and breast PDX TMAs or FFPE slides revealed heterogeneous expression levels of CD47 between different models or even different tumor cells within same model. In addition, IHC scores were not entirely correlated with the RNA levels of the same model. Conclusion: The lack of consistency between CD47 RNA expression and protein measurement warrants further investigation into how the heterogeneity, identified by IHC assessment, could potentially correlate with the pharmacology of specific CD47 blockers thus, predicting response and setting the stage for the development of the treatment companion diagnostics. No conflict of interest.

ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers.

Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates

Cadherin-17 as a target for the immunoPET of adenocarcinoma

ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment.

Preclinical Evaluation of 89Zr/177lu-Labeled Amatuximab for Theranostic Application in Pancreatic Ductal Adenocarcinoma

An Integrin-αvβ6/α5β1-Bitargeted Probe for the SPECT Imaging of Pancreatic Adenocarcinoma in Preclinical and Primary Clinical Studies.

Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors

68Ga-HBED-CC-WL-12 PET in Diagnosing and Differentiating Pancreatic Cancers in Murine Models

Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors

Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe.

124I-labeled anti-CD147 antibody for noninvasive detection of CD147-positive pan-cancers: construction and preclinical studies

PET Imaging of Peptide Probe Al[ 18 F]F-NOTA-PCP1 for Monitoring the Engagement of PD-L1 Antibodies in Tumors

18F-Labeled Dimer-Sansalvamide A Cyclodecapeptide: A Novel Diagnostic Probe to Discriminate Pancreatic Cancer from Inflammation in a Nude Mice Model.

Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer

A Novel Plectin/integrin-Targeted Bispecific Molecular Probe for Magnetic Resonance/near-Infrared Imaging of Pancreatic Cancer.

800CW Dye and 89zr Dual-labeled Antibody for the PET/NIRF/Cerenkov Multi-modality Imaging of ICAM-1 (CD54) in Pancreatic Cancer

Developing a Preclinical CD47 IHC Assay Using Patient-Like Samples for the Development of a Companion Diagnostic for CD47-targeting Treatments

ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma

Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma